Formulation Optimization & Bioavailability Enhancement
INQUIRY
From "Soluble" to "Useful"
Poor aqueous solubility remains one of the most critical barriers in modern drug development. While cyclodextrins (CDs) are widely recognized for their solubilization capability, true formulation success is defined by in vivo performance rather than solubility alone.
Our cyclodextrin-based formulation optimization service is designed to bridge this gap. By integrating rational CD selection, hybrid delivery system design, and dissolution–absorption correlation strategies, we help transform soluble APIs into clinically effective and developable drug products.
Our goal: Not just making drugs soluble — but making them bioavailable.
Cyclodextrin-Based Solubilization Formulation Design
Effective CD formulation begins with understanding the molecular compatibility between API and cyclodextrin. We provide systematic formulation strategies based on:
- API physicochemical properties (logP, pKa, crystal form)
- Inclusion complex formation mechanisms
- Solubility–release balance optimization
Key formulation considerations include:
- Selection of native or substituted CDs (α-, β-, γ-CD, HP-β-CD, SBE-β-CD, etc.)
- Optimization of CD/API molar ratio to avoid release inhibition
- Application-specific formulation design for solid and liquid dosage forms
This approach enables predictable solubility enhancement while maintaining efficient drug release and absorption potential.
Hybrid Drug Delivery Systems with Cyclodextrins—Synergistic Formulation Strategies
In many challenging cases, cyclodextrins alone are insufficient to overcome absorption limitations. We therefore develop hybrid delivery systems in which CDs function as synergistic components rather than standalone excipients.
Typical combination strategies include:
- Cyclodextrins with polymeric or lipid-based nanoparticles
- CD-assisted self-emulsifying drug delivery systems (SEDDS/SMEDDS)
- CD-modulated sustained- or controlled-release formulations
In these systems, cyclodextrins can improve drug loading efficiency, stabilize supersaturation, and regulate drug release kinetics.
Careful system integration avoids formulation conflicts such as phase separation, competitive encapsulation, or reduced stability.
Fig. 1 Cyclodextrin-based polymer nanoparticle delivery systems are used for chemotherapy drugs, combination therapies, and therapeutic applications[1].
Dissolution Behavior & In Vivo Performance Optimization—From In Vitro Solubility to In Vivo Exposure
High solubility does not always translate into high bioavailability. Our formulation strategy therefore focuses on dissolution behavior optimization with clear in vivo relevance.
Our technical focus includes:
- Modulating dissolution profiles to prevent rapid precipitation
- Improving pH-independent drug release
- Supporting IVIVC-oriented formulation design
- Reducing variability in gastrointestinal absorption
By controlling the dynamic interaction between cyclodextrin complexes and physiological environments, we help achieve consistent and predictable systemic exposure.
Stability & Developability Considerations—Formulations Ready for Scale-Up and Regulatory Pathways
Beyond performance, successful drug products must demonstrate long-term stability and industrial feasibility. We evaluate cyclodextrin formulations with respect to:
- Chemical and physical stability of the API
- Crystal form control and polymorphism risk
- Hygroscopicity and viscosity management
- Compatibility with spray drying, lyophilization, and large-scale manufacturing
Application Scenarios
Our cyclodextrin-based formulation optimization services are particularly suited for:
a. Poorly soluble oral small-molecule drugs (BCS Class II & IV)
b. Injectable formulations with solubility-limited APIs
c. Local delivery systems (ocular, dermal, nasal)
d. Reformulation and lifecycle management of existing drugs (505(b)(2) strategies)
Service Deliverables & Collaboration Model
Our formulation optimization service typically delivers:
- Cyclodextrin screening and formulation feasibility studies
- Rational formulation design recommendations
- Solubility, dissolution, and stability evaluation support
- Customized cyclodextrin materials and technical consultation
We work closely with our partners to ensure that each formulation strategy aligns with development timelines, regulatory expectations, and clinical objectives.
Discuss Your Formulation Challenges with Our Experts
Struggling with poor solubility, inconsistent dissolution, or limited bioavailability?
Our cyclodextrin-based formulation experts support rational excipient selection, inclusion complex design, and performance-driven optimization strategies tailored to your API and dosage form.
Whether you are at early screening or late-stage development, we help translate formulation concepts into reproducible and developable solutions. Contact us now to discuss your formulation strategy.
Frequently Asked Questions (FAQ)
Is cyclodextrin inclusion suitable for my drug candidate?
Cyclodextrin inclusion is particularly suitable for poorly water-soluble small molecules, especially those with aromatic or hydrophobic moieties. If solubility, stability, or formulation flexibility is limiting your development progress, cyclodextrin-based inclusion is often a viable pre-formulation strategy. Our evaluation starts with your molecule's physicochemical profile rather than assuming a one-size-fits-all approach.
At what stage of development should cyclodextrin inclusion be explored?
Cyclodextrin inclusion can be introduced as early as pre-formulation or lead optimization and remains relevant through formulation development and CMC stages. Early evaluation helps avoid downstream reformulation risks, while later-stage optimization can address solubility or stability issues encountered during scale-up or route-of-administration changes.
Can cyclodextrin inclusion support injectable formulations?
Yes. Certain cyclodextrin derivatives, such as HPβCD and SBE-β-CD, are widely used in parenteral formulations to improve solubility and reduce reliance on organic solvents. Selection depends on drug charge, dose level, and regulatory considerations, which are assessed during carrier screening.
Will inclusion complex development affect downstream formulation or scale-up?
Inclusion development is conducted with downstream formulation and manufacturability in mind. We consider reproducibility, process feasibility, and compatibility with common dosage forms to minimize development risk and facilitate future scale-up.
What information do I need to provide to start a project?
Basic information such as molecular structure, solubility profile, intended administration route, and development stage is typically sufficient to initiate evaluation. Additional data can further refine selection and optimization but is not mandatory at the outset.
References
- Kali G.; et al. Cyclodextrins and derivatives in drug delivery: New developments, relevant clinical trials, and advanced products. Carbohydr Polym. 2024, 324, 121500.
- Mura P. Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: A review. Journal of Pharmaceutical and Biomedical Analysis. 2014, 101, 238-250.
It should be noted that our our products and services are for research use only, not for clinical use.
